The pharmacokinetics and clinical tolerability of ascending single doses of BNC210 in healthy volunteers.

Trial Profile

The pharmacokinetics and clinical tolerability of ascending single doses of BNC210 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Anxiety disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Aug 2010 Results presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology.
    • 03 Mar 2010 Clinical Trial Results Confirm Safety and Indicate Reduced Stress Hormone Levels, according to a media release from Bionomics.
    • 08 Dec 2009 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top